• Tian Lin, Dayana Maita, Sujatha R Thundivalappil, Frank E Riley, Jasmin Hambsch, Linda J Van Marter, Helen A Christou, Lorenzo Berra, Shawn Fagan, David C Christiani, and H Shaw Warren.
• Department of Pediatrics, Infectious Disease Unit, Massachusetts General Hospital, and Harvard Medical School, 149 13th Street, Charlestown, MA, 02129, USA. tlin7@mgh.harvard.edu.
• Crit Care. 2015 Jan 1;19:166.

IntroductionCell-free plasma hemoglobin is associated with poor outcome in patients with sepsis. Extracellular hemoglobin and secondarily released heme amplify inflammation in the presence of microbial TLR ligands and/or endogenous mediators. Hemopexin, a plasma protein that binds heme with extraordinary affinity, blocks these effects and has been proposed as a possible treatment approach to decrease inflammation in critically ill patients.MethodsWe studied mouse models of endotoxemia, burn wound infections and peritonitis in order to assess if a repletion strategy for hemopexin might be reasonable. We also measured hemopexin in small numbers of three patient populations that might be logical groups for hemopexin therapy: patients with sepsis and ARDS, patients with severe burns, and premature infants.ResultsDespite severe disease, mean plasma hemopexin levels were increased above baseline in each murine model. However, plasma hemopexin levels were decreased or markedly decreased in many patients in each of the three patient populations.ConclusionsPotentially different behavior of hemopexin in mice and humans may be important to consider when utilizing murine models to represent acute human inflammatory diseases in which heme plays a role. The findings raise the possibility that decreased hemopexin could result in insufficiently neutralized or cleared heme in some patients with ARDS, burns, or in premature infants who might be candidates to benefit from hemopexin administration.

30 keywords...

hide…